Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer



Status:Archived
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:August 2010
End Date:July 2012

Use our guide to learn which trials are right for you!

An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 "Regorafenib", Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer


This is a multi-center, open-label, non-randomized Phase I study to define the safety
profile, maximum tolerated dose (MTD) and potential pharmacokinetic interaction of
regorafenib in combination with pemetrexed and cisplatin in patients with Stage IIIB or
Stage IV nonsquamous Non-Small Cell Lung Cancer (NSCLC) and to determine the impact of the
combined administration on the pharmacokinetics of regorafenib, pemetrexed, and cisplatin.

In Part A of this trial, regorafenib will be administered in a sequential dosing with a
seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib
will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break.

In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21.
Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the
pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing.



We found this trial at
4
sites
Newington, Connecticut
?
mi
from
Newington, CT
Click here to add this to my saved trials
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Charlotte, North Carolina
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Henderson, Nevada
?
mi
from
Henderson, NV
Click here to add this to my saved trials